Source:http://linkedlifedata.com/resource/pubmed/id/12548512
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2003-1-27
|
| pubmed:abstractText |
Recurrent hepatitis B infection after liver transplantation was previously frequent and associated with significant allograft failure and mortality. Recurrence rates of hepatitis B were improved with the use of passive immunoprophylaxis with hepatitis B immune globulin, and later, lamivudine monotherapy. Combination prophylaxis with intravenous hepatitis B immune globulin and lamivudine substantially decreased rates of hepatitis B recurrence, but intravenous administration of hepatitis B immune globulin was expensive and associated with significant adverse effects. In the current study, 59 patients receiving primary liver transplantation for chronic hepatitis B infection were prospectively followed up after converting from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine. All patients tolerated intramuscular hepatitis B immune globulin well. At a median follow-up of 511 days after conversion to intramuscular hepatitis B immune globulin, 58 of 59 patients (98.3%) were hepatitis B surface antigen-negative. Twenty-one patients (35.6%) required a median of one supplemental intravenous hepatitis B immune globulin infusion to maintain therapeutic antibody levels. Economic analysis showed an average cost-effectiveness ratio for combination intramuscular hepatitis B immune globulin plus lamivudine of $52,600 per recurrence prevented, which was far below the cost of lamivudine monotherapy and of intravenous hepatitis B immune globulin alone or in combination with lamivudine. These results suggest that intramuscular administration of hepatitis B immune globulin in combination with lamivudine offers a safe, effective, and cost-effective approach to preventing hepatitis B recurrence after orthotopic liver transplantation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1527-6465
|
| pubmed:author |
pubmed-author:BusuttilRonald WRW,
pubmed-author:DurazoFranciscoF,
pubmed-author:EdelsteinMarcM,
pubmed-author:FarmerDouglasD,
pubmed-author:GhobrialRafik MRM,
pubmed-author:GoldsteinLeonardL,
pubmed-author:HanSteven-HuySH,
pubmed-author:HoltCurtisC,
pubmed-author:HuRenaR,
pubmed-author:KunderGreggG,
pubmed-author:MartinPaulP,
pubmed-author:SaabSammyS
|
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
182-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12548512-Adult,
pubmed-meshheading:12548512-Aged,
pubmed-meshheading:12548512-Cost-Benefit Analysis,
pubmed-meshheading:12548512-Drug Costs,
pubmed-meshheading:12548512-Drug Therapy, Combination,
pubmed-meshheading:12548512-Female,
pubmed-meshheading:12548512-Graft Survival,
pubmed-meshheading:12548512-Hepatitis B,
pubmed-meshheading:12548512-Humans,
pubmed-meshheading:12548512-Immunoglobulins,
pubmed-meshheading:12548512-Injections, Intramuscular,
pubmed-meshheading:12548512-Injections, Intravenous,
pubmed-meshheading:12548512-Lamivudine,
pubmed-meshheading:12548512-Liver Transplantation,
pubmed-meshheading:12548512-Male,
pubmed-meshheading:12548512-Middle Aged,
pubmed-meshheading:12548512-Postoperative Period,
pubmed-meshheading:12548512-Recurrence,
pubmed-meshheading:12548512-Reverse Transcriptase Inhibitors,
pubmed-meshheading:12548512-Safety,
pubmed-meshheading:12548512-Survival Analysis,
pubmed-meshheading:12548512-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.
|
| pubmed:affiliation |
Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA. shbhan@ucla.edu
|
| pubmed:publicationType |
Journal Article
|